Genomic Valley Biotech returns to profitability in FY26
Genomic Valley Biotech Limited returned to profitability in FY26 with a net profit of ₹3,03,041, reversing a net loss of ₹35,60,932 in the previous year. The turnaround was driven by a reduction in total expenses to ₹22,74,590, despite revenue from operations falling to ₹26,75,000 from ₹84,39,394. For the quarter ended March 31, 2026, the company reported a net loss of ₹81,745 on revenue of ₹3,75,000. The Board appointed Mr. Navjyoti Kumar Jha as Internal Auditor for FY27.
*this image is generated using AI for illustrative purposes only.
Genomic Valley Biotech Limited returned to profitability in the financial year ended March 31, 2026, posting a net profit of ₹3,03,041 compared to a net loss of ₹35,60,932 in the previous year. The turnaround was driven by a significant reduction in total expenses, which fell to ₹22,74,590 in FY26 from ₹40,69,678 in FY25, despite a decline in revenue from operations to ₹26,75,000 from ₹84,39,394. The company recorded a basic earnings per share (EPS) of ₹0.10 for the year, against a negative EPS of ₹1.17 in FY25.
For the quarter ended March 31, 2026, the company reported a net loss of ₹81,745 on revenue from operations of ₹3,75,000. The loss before tax for the quarter stood at ₹15,624, with total expenses amounting to ₹3,59,376. In comparison, the quarter ended March 31, 2025, saw a net loss of ₹8,34,895 on total revenue of ₹26,35,770.
Financial Performance
The reduction in expenses was primarily due to lower employee benefits costs, which decreased to ₹10,59,000 in FY26 from ₹12,08,645 in the prior year. However, depreciation and amortization expense increased to ₹37,064 from ₹25,414, and other expenses rose to ₹11,78,525 from ₹8,21,824. The tax expense for the quarter ended March 31, 2026, included a current tax of ₹1,00,000 and a deferred tax adjustment of -₹2,631.
Financial Position
The company's total assets as of March 31, 2026, stood at ₹4,24,95,674, slightly lower than ₹4,35,65,624 in the previous year. Total equity increased to ₹3,92,84,574 from ₹3,89,81,533. Trade receivables rose to ₹2,31,77,445 from ₹2,21,44,945, while cash and cash equivalents decreased sharply to ₹42,936 from ₹2,28,976.
| Metric | FY26 (₹) | FY25 (₹) |
|---|---|---|
| Revenue from Operations | 26,75,000 | 84,39,394 |
| Total Expenses | 22,74,590 | 40,69,678 |
| Net Profit for the Period | 3,03,041 | -35,60,932 |
| Basic EPS | 0.10 | -1.17 |
Board Appointments
The Board of Directors approved the appointment of Mr. Navjyoti Kumar Jha as the Internal Auditor for the financial year 2026-27. Mr. Jha holds a Bachelor of Commerce degree and brings 26 years of experience to the role. He is not related to any director of the company. The statutory auditors, M/s ANDROS & Co. Chartered Accountants, issued an unmodified opinion on the audited standalone financial results.
Historical Stock Returns for Genomic Valley Biotech
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -4.98% | +7.61% | +25.70% | +41.36% | -35.69% | +48.27% |
Can Genomic Valley Biotech sustain profitability in FY27 given that its turnaround relied heavily on cost-cutting rather than revenue growth, with operations revenue declining nearly 68% year-over-year?
What strategic initiatives is Genomic Valley Biotech pursuing to reverse the sharp decline in revenue from operations and rebuild its client pipeline in the genomics/biotech sector?
With cash and cash equivalents dropping to just ₹42,936 and trade receivables rising to ₹2.31 crore, how will the company manage its liquidity and accelerate collections to fund day-to-day operations?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
